Purdue Pharma completed a late-stage trial of its extended-release--and abuse-deterrent--formulation of hydrocodone bitartrate earlier this year and filed for FDA approval on April 30. Observers say that, if Purdue is successful, the FDA could force Zogenix to pull Zohydro, which doesn't include tamper-resistant features.
Market Data 
Markets 
AI
